Granite Point Capital Management, L.P. Macrogenics Inc Transaction History

Granite Point Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 13, 2018	SELL	$19.78 - $24.67 $791,200 - $986,800	-40,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$18.89 - $32.46 $17,001 - $29,214	-900 Reduced 2.2%	40,000 $1.01 Million
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $634,768 - $774,646	40,900	40,900 $756,000

169

62.5M

819K

79.4K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $302M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.